ERBB2 and breast cancer: Furthermore, in the prospective phase 2 TUXEDO-1 trial of 15 patients with HER2+ BC and active brain metastases, treatment with T-DXd led to a high intracranial response rate (73.3%; 95% CI, 48.1–89.1) (11).